All data are based on the daily closing price as of November 18, 2026
s
SK Biopharmaceuticals
326030.KO
64.53 USD
-2.11
-3.17%
Overview
Last close
64.53 usd
Market cap
5.05B usd
52 week high
95.49 usd
52 week low
50.09 usd
Target price
98.58 usd
Valuation
P/E
17.3831
Forward P/E
81.3008
Price/Sales
7.81
Price/Book Value
6.6671
Enterprise Value
4.99B usd
EV/Revenue
7.1515
EV/EBITDA
9.0863
Key financials
Revenue TTM
647.04M usd
Gross Profit TTM
608.09M usd
EBITDA TTM
239.72M usd
Earnings per Share
3.85 usd
Dividend
N/A usd
Total assets
916.79M usd
Net debt
N/A usd
About
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, development, and commercialization of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL27969 for treatment of advanced solid tumors; SKL13865 clinical trials to treat attention deficit/hyperactivity disorder; and SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder. The company was founded in 1993 and is headquartered in Seongnam-si, South Korea. SK Biopharmaceuticals Co., Ltd. operates as a subsidiary of SK Inc.